



Provincial Health Services Authority

MEDICAL ALERT

NAME _____

is being treated with
quizartinib:

QT interval prolongation

**ALWAYS CARRY THIS CARD AND SHOW TO ALL
PHYSICIANS INCLUDING ANESTHETISTS**

Quizartinib is associated with QT interval prolongation, which may increase the risk of ventricular arrhythmias or torsades de pointes. Quizartinib is contraindicated in patients with congenital QT syndrome or history of ventricular arrhythmias or torsades de pointes. Monitor serum electrolytes and correct any abnormalities. Avoid non-essential medications that prolong QT interval.

FOR MORE INFORMATION:

BC Cancer - Abbotsford604-851-4710
BC Cancer - Kelowna250-712-3900
BC Cancer - Prince George.....250-645-7300
BC Cancer - Surrey.....604-930-4055
BC Cancer - Vancouver.....604-877-6000
BC Cancer - Victoria.....250-519-5500
VGH Leukemia/BMT Program.....604-875-4111
www.bccancer.bc.ca/cdm

Rev 1 Oct 2026